BRIEF-Briacell’S Bria-Imt™ Demonstrates Survival Advantage Over Trodelvy® And Control Group In Metastatic Breast Cancer

Reuters
Jul 11
BRIEF-Briacell’S Bria-Imt™ Demonstrates Survival Advantage Over Trodelvy® And Control Group In Metastatic Breast Cancer

July 11 (Reuters) - Briacell Therapeutics Corp BCT.TO:

  • BRIACELL’S BRIA-IMT™ DEMONSTRATES SURVIVAL ADVANTAGE OVER TRODELVY® AND CONTROL GROUP IN METASTATIC BREAST CANCER

  • BRIACELL THERAPEUTICS CORP - NO TREATMENT-RELATED DISCONTINUATIONS REPORTED FOR BRIACELL'S BRIA-IMT

  • BRIACELL THERAPEUTICS CORP - ANNOUNCES UPDATED PHASE 2 DATA FOR BRIA-IMT

  • BRIACELL THERAPEUTICS CORP - BRIA-IMT SHOWS 13.9 MONTHS OS IN TNBC

  • BRIACELL THERAPEUTICS CORP - BRIA-IMT SHOWS 17.3 MONTHS OS IN HR+ BREAST CANCER

Source text: ID:nGNX4q7xFD

Further company coverage: BCT.TO

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10